-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $30

Benzinga·12/10/2025 14:39:54
Listen to the news
Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $24 to $30.